Previous Statements by MYL
» Mylan, Inc. - Analyst/Investor Day
» Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Mylan's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
K-Mart pharmacies lowered the cost of its generic epinephrine auto-injector pens to $199.99